Seven ministries have issued a message that this area of health care will face great opportunities

Pharmaceutical Network Industry Dynamics: Mental illness is a group of neurological disorders that are mainly manifested in behavioral and psychological disorders.
recent years, with the economic development and social transformation, mental health work has become more and more extensive, more and more sensitive, mental and psychological problems and social security and stability, and public happiness and other issues intertwined and superimposed and so on increasingly prominent.
to further strengthen the construction of the psychiatric service system, enhance the capacity of psychiatric services, and promote the development of high-quality medical services.
recently, the National Health and Health Commission, the National Development and Reform Commission, the Ministry of Education, the Ministry of Finance, the Ministry of Human Resources and Social Security, the State Administration of Traditional Chinese Medicine and the State Administration of Health Insurance jointly formulated and issued the Opinions on Strengthening and Improving Psychiatric Medical Services.
Specifically, "Opinions" put forward systematic proposals from the seven aspects of overall requirements and main objectives, strengthening the construction of the psychiatric medical service system, strengthening the construction of the psychiatric professionals, strengthening the capacity-building of the psychiatric medical services, strengthening the quality management of the psychiatric medical treatment, mobilizing the enthusiasm of the psychiatric medical personnel and organizing the implementation.
, psychotherapy services have received very much policy attention.
"Opinion" calls for the overall improvement of the price management of psychiatric medical services, and the inclusion of the prices of psychiatric and psychotherapy medical services in the deepening of medical service price reform.
and in accordance with the integration of service output, labor input and other related price items, improve the bed-day pricing policy.
the implementation of dynamic adjustment of the price of medical services, the focus will be on adjusting the price of technical services, including mental and psychotherapy.
to do a good job of price adjustment, medical insurance payments and medical control fees and other policies.
industry said that the inclusion of psychotherapy services in health insurance, and price adjustment, will help to enhance the community's awareness of the value of psychotherapy services, and further promote the social status of psychotherapy professionals.
, the market for psychotherapy drugs may or may not be a boost.
it is understood that mental illness is prone to recurrent attacks, treatment cycle is long, patients need long-term inpatient care services, so the cost of treatment of mental illness has been relatively high.
with the continuous construction and improvement of China's basic medical security system, more and more people realize the existence and severity of mental illness, and began to pay attention to the diagnosis and treatment of mental illness.
these factors, the market for psychiatric medical services began to develop rapidly.
statistics show that by the end of 2015, there were more than 16 million severe mental disorders in China, and 4.297 million people with severe mental disorders were registered.
, in 2019, China's urban public medical institutions in the market for psychosysurological drugs sales have reached 77.4 billion.
with the promotion of the "Healthy China" strategy and the change of the society's understanding of depression and the concept of medical treatment, the industry generally believes that the domestic demand for psychotherapy drugs is expected to grow, and there is great room for market development.
facing an increasingly large drug market, domestic pharmaceutical companies are accelerating the distribution of psychotherapy drugs.
that in recent years, there have been Zhengda Qing, Haizheng Pharmaceuticals, Howson Pharmaceuticals and Yangzijiang and other pharmaceutical companies have declared schizophrenia generic drugs on the market.
year, there are also a number of pharmaceutical companies out of the drug declaration of new progress.
For example, Jingxin Pharmaceuticals has previously announced that JX11502MA capsules, the company's innovative drug for the treatment of adult schizophrenia, have been approved for clinical trials, and Yangzijiang Pharmaceuticals has announced the acceptance of a market application for a generic drug called Lulassin ketone tablets for the treatment of adult schizophrenia under Nanjing Hailing Pharmaceuticals.